A 52-year-old man from Delhi presents with a 3-month history of progressive muscle pain and weakness in his legs. He was started on atorvastatin 40 mg daily 6 weeks ago for hypercholesterolaemia (total cholesterol 320 mg/dL, LDL 240 mg/dL). On examination, he has proximal muscle tenderness and mild elevation of creatine kinase (CK 850 U/L, normal <200). His lipid panel shows total cholesterol 180 mg/dL and LDL 95 mg/dL. Renal function and liver enzymes are normal. Which of the following best explains the biochemical mechanism underlying his current clinical presentation?

Explanation

## Statin-Induced Myopathy: Biochemical Mechanism ### Clinical Context This patient presents with classic statin-induced myopathy—muscle pain (myalgia) and elevated CK occurring within 6–8 weeks of initiating a statin. The temporal relationship and resolution of hypercholesterolaemia confirm the statin is working. ### Biochemical Mechanism of Statin Toxicity **Key Point:** Statins inhibit HMG-CoA reductase, which catalyses the rate-limiting step in cholesterol synthesis. However, this same enzyme is upstream of multiple isoprenoid intermediates essential for non-cholesterol functions. ### The Ubiquinone (CoQ10) Depletion Pathway HMG-CoA reductase catalyses the conversion of HMG-CoA to mevalonate. Mevalonate is the precursor for: 1. **Cholesterol** (via squalene → lanosterol pathway) 2. **Isoprenoids** (farnesyl-PP and geranylgeranyl-PP) - These activate small GTPases (Ras, Rho, Rac) critical for cell signalling 3. **Ubiquinone (CoQ10)** — a critical electron carrier in the mitochondrial respiratory chain (Complex I–III) When statins block mevalonate production, CoQ10 synthesis is impaired. Skeletal muscle is highly oxidative and energy-dependent; CoQ10 depletion causes: - Reduced ATP synthesis via oxidative phosphorylation - Increased reactive oxygen species (ROS) production - Mitochondrial dysfunction → myocyte apoptosis and necrosis - Elevated CK release **High-Yield:** CoQ10 supplementation has shown benefit in some statin-myopathy cases, supporting this mechanism. ### Why Other Mechanisms Are Secondary | Mechanism | Role in Statin Effect | Relevance to Myopathy | |-----------|----------------------|----------------------| | Dolichol depletion | Impairs N-linked glycosylation | Rare; affects protein folding globally, not muscle-specific | | Isoprenoid depletion | Impairs Rho/Rac signalling | Contributes to myopathy but less critical than CoQ10 | | LDL receptor ↑ | Intended therapeutic effect | Does not cause muscle toxicity | | Oxidised LDL uptake | Inflammatory pathway | Not the primary mechanism of acute myopathy | **Clinical Pearl:** Statin-induced myopathy is dose- and lipophilicity-dependent. Atorvastatin (lipophilic) and simvastatin have higher myopathy risk than pravastatin (hydrophilic). ### Management Approach ```mermaid flowchart TD A[Statin-induced myalgia + elevated CK]:::outcome --> B{CK > 5× ULN?}:::decision B -->|Yes| C[Stop statin immediately]:::urgent B -->|No| D{Symptoms severe?}:::decision D -->|Yes| E[Discontinue or switch to hydrophilic statin]:::action D -->|No| F[Continue; consider CoQ10 supplementation]:::action C --> G[Rechallenge after 4–6 weeks if needed]:::action E --> H[Recheck CK and symptoms in 2 weeks]:::action ```